NAV™ rAAV Vectors
REGENX’s proprietary technology uses recombinant adeno-associated viral (rAAV) vectors for the delivery of new genetic materials to cells. rAAVs are uniquely designed by nature to effectively deliver genetic material to host cells.
REGENX NAV™ rAAV Vector Technology has been developed through substantial investment in research and development to address the requirements of using viral vectors in vivo, R&D which has resulted in platforms that are optimized to provide significant advantages over other existing methods.
Advantages of “traditional” rAAV:
- Non-pathogenic
- Non-replicating
- Efficient for delivering genes in vivo
REGENX’s NAV™ Technology provides further advantages beyond “traditional” rAAV including:
- Faster onset of gene expression
- Long-lasting, stable gene expression
- High tissue selectivity
- High titer manufacture
For more information about the applications of REGENX NAV Technology, please visit these pages:
